It's only fitting that a relatively slow and otherwise generic week of US biopharma news was highlighted by FDA's first full approval of a copycat intranasal naloxone product to counter opioid overdose. The honor went to Teva Pharmaceutical Industries Ltd., which previously received a tentative approval for its generic Narcan (naloxone hydrochloride) nasal spray product in June 2018.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?